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Non-cardiogenic pulmonary oedema, an early manifestation of the adult respiratory disease syndrome, is a serious
complication following major vascular surgery. Hypovolaemia, ischaemia-reperfusion injury, massive blood transfusion,
transient sepsis and transient endotoxaemia are insults responsible for initiating the process in vascular surgical patients.
Free radicals, cytokines and humoral factors released secondary to the above insults activate neutrophils and facilitate
their interaction with the endothelium. Activated neutrophils marginate through the endothelium where they are responsible
for tissue injury by the release of free-radicals and proteases. The lungs are a large reservoir of neutrophils and bear a
significant part of the injury. Conventional therapy includes treating the underlying condition and providing respiratory
support. A better understanding of the pathophysiology of this process has led to new experimental treatment options.
Novel therapeutic interventions have included the use of compounds to scavenge free radicals, anti-cytokine antibodies,
extracorporeal lung support, nitric oxide and artificial surfactant therapy. The multifactorial nature of this process makes
it unlikely that a single “magic bullet” will solve this problem. It is more likely that a combination of preventative,
prophylactic and therapeutic modalities may reduce the mortality of this condition.
Introduction The importance of non-cardiogenic pulmonary oed-
ema is that it may be the first clinical sign of a larger
Pulmonary complications contribute significantly to process, the systemic inflammatory response syn-
drome, which when left unchecked leads to multiplethe postoperative morbidity and mortality data re-
ported following major vascular surgery.1 Pre-existing organ failure.10,11 Due to intensive preoperative op-
timisation of cardiac function, some recent series haverespiratory disease, inadequate postoperative epidural
analgesia and inadequate postoperative physiotherapy reported multiple organ failure as the leading cause
of death following abdominal aortic aneurysm surgery,leading to pulmonary atelectasis and infection have
traditionally been held responsible for postoperative relegating death due to cardiac complications to sec-
ond place.12,13respiratory complications.2,3 Events that occur during
vascular surgical procedures can trigger a set of events In this review the pathophysiology of factors con-
that lead to acute pulmonary injury.4,5 This in turn has tributing to non-cardiogenic pulmonary oedema and
been reported to lead to pulmonary oedema of non- therapeutic manoeuvres that may limit this disease
cardiogenic origin progressing to the adult respiratory process will be discussed.
distress syndrome and respiratory failure.6,7 A large
multicentre prospective study found that respiratory
failure complicates 8% of patients undergoing non-
ruptured abdominal aortic surgery8 and 47% of
patients undergoing surgery for a ruptured abdominal
The Adult Respiratory Distress Syndromeaortic aneurysm.9
The adult respiratory distress syndrome (ARDS) was
first described during the Vietnam War in victims
* Please address all correspondence to: R. Pararajasingam, Uni- surviving multiple trauma, shock and burns.14 It isversity Department of Surgery, Leicester General Hospital NHS
Trust, Leicester LE5 4PW, U.K. now known that there are many aetiological factors
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Table 1. Aetiology of acute lung injury. infiltration with blood, oedema fluid and inflammatory
infiltrate. Small airway collapse leads to bronchialDirect lung injury:
Aspiration pneumonia obstruction and provides an ideal environment for
Infectious pneumonia superimposed infection. At this stage lung surfactant
Other pneumonitis: oxygen, smoke inhalation, radiation levels are found to be depleted.17,18,22 Late featuresDirect Trauma: lung contusion, penetrating chest injury
Near drowning include eventual interstitial fibrosis.23
Fat embolism
Distant injury:
Sepsis syndromes: inflammation, necrosis, infection
Ischaemia reperfusion injury
Pathophysiology of Acute Lung Injury in VascularMultiple trauma
Burns Surgery
Shock or hypoperfusion
Acute pancreatitis
The aetiological factors responsible for acute lungBlood transfusion related acute lung injury
injury in vascular surgical procedures include aortic
cross-clamping and the consequent ischaemia-re-
for ARDS, which can be conveniently classified into perfusion injury, hypovolaemia, shock, transient
direct lung injury and distant lung injury (Table 1). sepsis, transient endotoxaemia and massive blood
The clinical features of ARDS are of progressive transfusion.4,5,7,22,24–28
hypoxia leading to respiratory failure. The initial fea- The processes that cause the lung damage are ini-
tures usually present about 16–24 h after the initiating tiated in areas quite remote from the lung (Fig. 1).
insult with little more than hypoxia, tachypnoea and During reperfusion, free radicals are formed at the
tachycardia. Clinically there are minimal signs of pul- sites subjected to the ischaemic insult (most commonly
monary oedema on auscultation and the chest X-ray the lower limbs). The reperfusion process floods these
is normal. Over the next 24 h the patient will develop free radicals into the systemic circulation where they
increasing dyspnoea and hypoxia with mild clinical can initiate damage either directly by themselves, in-
signs such as inspiratory rhonchi. The chest X-ray is directly by activating neutrophils and the endothelium
usually non-specific at this stage, showing diffuse or by providing a stimulus for the further production
alveolar shadows which are often attributed to in- of cytokines. A similar process occurs in the hypo-
fection or fluid overload. The syndrome progresses to perfused regions during shock. The process of re-
a picture of severe hypoxia, reduced lung compliance suscitation washes the toxic metabolites into the
secondary to alveolar collapse, inflammatory in- systemic circulation where they initiate lung damage.
filtration of the lungs, oedema, surfactant depletion, The metabolites involved will be discussed shortly,
increased airway resistance and superimposed in- but it is important to note that most of these mediators
fection, making ventilation difficult. Chest X-ray at encourage neutrophil–endothelial interaction; leading
this stage will show the typical “ground-glass” ap- to migration of neutrophils into tissues where damage
pearance in both lungs.15–19 is caused by the degranulation of these cells.26,29,30 The
Established ARDS has a mortality rate of about 60%. pulmonary vascular bed is known to store between
Advanced age, pre-existing lung disease, sepsis or 50–60% of the total circulating neutrophil pool, causing
the development of additional organ system failures major sequestration of neutrophils into pulmonary
increases the mortality rate to 70–90%.14,19,20 tissue making the lungs a major site of tissue damage
Post-mortem studies show that early pathological (Fig. 1).31 Neutrophils cause pulmonary damage by
changes in ARDS include pulmonary neutrophil se- releasing toxic metabolites including proteases and
questration and intravascular fibrin-platelet ag- free radicals.32 The factors responsible for acute lung
gregates. Subsequent injury to the alveolar-capillary injury can be conveniently grouped into four types
barrier leads to progressive lung inflammation and for descriptive purposes: free radicals, neutrophils,
pulmonary oedema. Increased numbers of neutrophils factors derived from the endothelium and humoral
marginate along the endothelial surfaces and migrate factors.
into the interstitium and the alveoli.18,21,22
The latter stages of ARDS are associated with in-
flammatory cell and fibroblast infiltration, pneumocyte
proliferation, gradual obliteration of the pulmonary Free radicals
microvasculature and some fibrosis. This explains the
progressive decrease in lung compliance. Progressive Ischaemia-reperfusion injury is an inevitable con-
sequence of recovery from acute limb ischaemia andpathological features include alveolar collapse due to
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Fig 1. Mechanism of development of acute lung injury.
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shock. Furthermore, aortic cross-clamping is inevitable further lipid degeneration and consequent cell mem-
brane damage. Proteins and DNA are also at risk fromduring open aortic surgery subjecting the lower torso
structural damage by free radicals.33,47to ischaemia-reperfusion. Free radicals are responsible
Superoxide free radicals react with endothelial cellsfor much of the systemic damage induced by re-
to promote the formation of inflammatory mediators,perfusion injury.33
the expression of endothelial leucocyte adhesionA free radical is any unstable molecule containing
molecules and inactivate nitric oxide formed by theone or more unpaired electrons; making them chem-
endothelium, thus encouraging the neutrophil–ically highly reactive.34 The main free radicals re-
endothelial interaction required for pulmonary leuco-sponsible for tissue damage in biological systems
sequestration.48,49include the superoxide ion (O2-) and the hydroxyl ion
(OH-).35 Also of note are nitric oxide (NO) both itself
and by its reaction with O2- to form OH- and the
peroxynitrite anion (ONOO-).36
LeucocytesThe xanthine dehydrogenase/oxidase system is re-
sponsible for the majority of free radicals formed
Neutrophils are the first line of defence against in-during ischaemia-reperfusion. Xanthine de-
vading organisms; however, during processes of pro-hydrogenase is a naturally occurring enzyme which
longed stimulation this potent armamentarium isunder normal circumstances converts hypoxanthine
directed against the host. Neutrophils cause tissue(a breakdown product of ATP metabolism) to uric
damage by two mechanisms; the generation of freeacid.38,39 During ischaemia, xanthine dehydrogenase is
radicals and the release of proteolytic degenerativeconverted to an isoform of this enzyme called xanthine
enzymes.oxidase (XO) by calcium activated proteases in isch-
The enzyme reduced nicotinamide adenine di-aemic tissue.39,40 Xanthine oxidase catalyses the con-
nucleotide oxidase transfers electrons from reducedversion of hypoxanthine to xanthine in the presence
nicotinamide adenine dinucleotide (NADPH) to mo-of molecular oxygen, releasing the superoxide (O2-) lecular oxygen generating superoxide ions:50,51free radical in the process.35,41
During ischaemia, tissue levels of xanthine oxidase 2O2+NADPH fi 2O2-+NADP++H+accumulate. Furthermore, depletion of ATP causes a
rise in tissue levels of hypoxanthine. Reperfusion of Superoxide dismutase is present in neutrophils, hence
ischaemic tissue with oxygenated blood introduces hydrogen peroxide is produced as described before. In
the second substrate for XO activity in abundance – the neutrophil, the enzyme myeloperoxidase catalyses
namely molecular oxygen. This causes a massive burst the formation of hypochlorous acid:52
in XO activity, leading to the release of large quantities
of the superoxide free radical.35,42 H2O2+Cl-+H+ fi HOCl+H2O
Superoxide dismutase is a naturally occurring en-
zyme which scavenges superoxide ions in physio- Hypochlorous acid is a potent oxidising and chlor-
logical circumstances. Superoxide dismutase converts inating agent. It reacts rapidly with primary amines
the superoxide ion to hydrogen peroxide.43–45 to produce N-chloramines, which are also potent ox-
idising agents. The cytotoxic effects of these oxidising
2O2-+2H+fi H2O2+O2 agents are mediated through the oxidation of sulphyl
groups, inactivation of haem proteins and cytochrome,
During pathological states of ischaemia-reperfusion, and the degradation of protein.42 Nitric oxide (NO) is
ferric iron is reduced to the ferrous state by O2. Ferrous also produced by activated neutrophils; when released
iron can donate an electron to hydrogen peroxide, together with superoxide ions the effects are likely to
which dismutates to form the hydroxyl radical (OH-). be locally cytotoxic, as NO reacts with superoxide to
The hydroxyl radical (OH-) is reputed to be the most form the highly injurious peroxinitrite and hydroxyl
reactive of free radicals in biological systems.46 radicals.36,53
Free radicals cause tissue damage by lipid per- The neutrophil’s cytosolic granules contain a potent
oxidation of cell membranes; a process initiated by the cocktail of proteolytic enzymes including elastase, gel-
removal of a hydrogen atom from a methylene group atinase and collagenase. These enzymes cause severe
positioned between two unsaturated bonds of a lipid damage to the pulmonary tissue and basement mem-
molecule. The result is a carbon centred lipid free brane.54
During normal physiological states up to 60% ofradical which in the presence of oxygen results in
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the total neutrophil pool is stored in the pulmonary cytes secrete chemotactic cytokines and MCP in large
quantities, attracting further inflammatory cells to thevasculature. Unlike the systemic vasculature, where
most of the cellular components marginate and interact region.63 Some of these monocytes transform into pul-
monary tissue macrophages with phagocytic prop-with the endothelium in the post-capillary venules,
neutrophils are found mainly in the low pressure erties and the capability of releasing free radicals and
proteases. Once activated in the pulmonary tissuepulmonary capillary bed.55 Neutrophils must change
from their loosely associated state in the pulmonary these cells play a central response in processing foreign
antigens and presenting them to lymphocytes. Theyvasculature to interact with the pulmonary endo-
thelium before they can initiate acute lung damage. are also a major source of chemotactic factors including
tumour necrosis factor, interleukins and arachidonicNumerous stimuli including the proinflammatory
cytokines (tumor necrosis factor a, interleukin-1, inter- acid metabolites.64,65 The cells derived from monocytes
play a greater role in the latter stages of acute lungleukin-8), complement, platelet-activating factor and
free radicals initiate neutrophil–endothelial interaction injury during the development of ARDS.
by initiating the endothelium to express a group of
endothelial leucocyte adhesion proteins and activate
neutrophils to express complementary glycoprotein
The endotheliumadhesion receptors. Superoxide also inactivates endo-
thelial nitric oxide – an endogenous anti-adhesion
In addition to the expression of leucocyte adhesionmolecule. As a consequence, neutrophils adhere to the
molecules which are vital to pulmonary leuco-first activated endothelium they encounter. The lungs
sequestration as described above, the endotheliumare a major site of neutrophil pooling and may undergo
produces a wide range of molecules and humoralsignificant tissue damage leading to acute lung injury.56
factors which regulate the development of acute lungThe neutrophil–endothelium interaction occurs in
injury. These substances include arachidonic acidtwo stages. Endothelial cells activated by pro-
metabolites, nitric oxide, cytokines and other humoralinflammatory cytokines express a group of leucocyte
factors.adhesion proteins called selectins: namely, endothelial
The enzyme phospholipase A2 releases arachidonicleucocyte adhesion molecule (ELAM or E-selectin),
acid from vascular endothelial cell membranes.intercellular adhesion molecule (ICAM or CD54) and
Arachidonic acid is further metabolised to prosta-granule membrane protein 140 (GMP140 or P-select-
cyclins and thromboxane by the cyclo-oxygenase path-in).57–59
way. Leukotrienes are formed by the action ofAll neutrophils express a group of proteins on their
lipoxygenase on arachidonic acid.66surface called lectin adhesion molecules (LECAM).
Prostacyclin causes vascular smooth muscle re-The LECAM receptor readily bonds to ELAM, hence
laxation and reduces platelet aggregation. It may pro-a large number of neutrophils are arrested from the
vide some protection during the development of acutecirculating pool and bind to endothelium.26 In-
lung injury, but endogenous prostacyclin is unstableflammatory mediators produced locally by the in-
and its synthesis is impaired by smoking, diabetes,flamed endothelium now stimulate the bound
atherosclerosis and increasing age.33 Increased throm-neutrophils to express a group of glycoproteins on their
boxane A2 (TA2) levels have been documented fol-cell surface called integrins. The important integrins
lowing aortic cross-clamping, ischaemia reperfusionexpressed by activated neutrophils include CD11b and
injury and shock.7,67,68 TA2 is a potent vasoconstrictor,CD18.60 The CD11b and CD18 receptors firmly attach
stimulates platelet aggregation and is a powerfulthemselves to ICAM, while LECAM receptors are
chemoattractant, facilitating neutrophil migrationrapidly shed. The integrin–selectin adhesion then al-
across activated endothelium.66,69 Leukotriene B4 (LB4)lows unopposed migration of the neutrophil between
is another important arachidonic acid metabolite in-endothelial cells.61 Activated neutrophils can now
volved in the genesis of acute lung injury. LB4 bindscause cellular damage by initiating the respiratory
to specific receptors on neutrophils and activatesburst and releasing free radicals and protease into
neutrophils to increase expression of surface CD18,this environment. Activated neutrophils also block the
encouraging neutrophil-endothelial interaction andmicrocirculation hindering normal blood flow.62
the generation of free radicals and proteases.70Circulating monocytes are recruited into areas of
Nitric oxide (NO) is an important endogenous me-inflammation in a similar manner to neutrophils.
diator involved in the control of normal vascular tone.Monocyte diapedesis across the endothelium requires
Local stimuli to the endothelium including shear stressthe endothelial expression of monocyte chemo-
attractant protein (MCP). Once in the intima, mono- and local hormones promote the liberation of NO as
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a by-product of the conversion of L-arginine to L- derivative produced by endothelial cells in response
to injury. PAF is an important mediator of ischaemia-citrulline by vascular endothelial constitutive nitric
reperfusion induced leucocyte chemotaxis. Within theoxide synthase. The net result of endogenous NO
microcirculation, PAF encourages platelet aggregation,on the vascular endothelium includes relaxation of
thrombus formation and alters microvascular per-vascular smooth muscle and inhibition of neutrophil
meability.80and platelet adhesion to the endothelium. In the lung
The endothelium is also capable of releasing com-NO also mediates bronchodilatation via a local non-
plement and cytokines. These humoral factors are alsocholinergic non-adrenergic pathway.53
produced in significant quantities by leucocytes andNO metabolism is profoundly affected during
other cells in the reticuloendothelial system.pathological states. Inflammation, sepsis and other
conditions that promote increased serum levels of
endotoxin and cytokines can lead to an increased
Humoral factorsproduction of endothelial nitric oxide by the up-
regulation of a second enzyme – inducible nitric oxide
Aortic cross-clamping, ischaemia-reperfusion injury,synthase (iNOS).71 Following induction, iNOS is active
haemorrhage and transient sepsis are all potent stimulifor >20 h and produces NO at over a thousand-fold
for the formation of a host of inflammatory humoralconcentrations compared to cNOS.72
factors including complement and cytokines. Ac-One of the most important effects of NO is vaso-
tivation of the complement cascade is indicated by andilation. This effect may reduce the “no-reflow” phe-
increase in serum levels of the active peptides C3anomenon commonly seen in ischaemia-reperfusion
and C5a as seen following major vascular surgicalinjury, whereby the microvascular circulation exhibits
procedures.81,82 These anaphylatoxins cause increasedcapillary spasm and plugging with activated leuco-
capillary permeabiliy and vasodilation. Increased com-cytes. The vasodilatory action of increased NO syn-
plement activity also enhances neutrophil chemotaxis,thesis may be a contributory factor to the hypotension
upregulates neutrophil CD18 receptor expression andseen during septic shock.73
promotes neutrophil free radical production and de-However, superoxide produced during ischaemia granulation.83
reperfusion is known to inactivate endogenous NO, Cytokines are a group of low molecular weight
hence promoting endothelial–neutrophil interaction.49 proteins produced by cells involved in the in-
Superoxide also reacts with NO to form the peroxi- flammatory response. These molecules are responsible
nitrite free radical (ONOO-), a free radical in its own for coordination and communication in the immune
right as well as a precursor of the hydroxyl anion.36 and inflammatory systems and include chemokines,
During chronic hypoxic states, including the events interleukins, growth factors and interferons. These
following acute lung injury, pulmonary NO synthesis factors have a transient action which is tightly reg-
and release is suppressed, accounting for some of ulated and are very active at low concentrations. They
the pulmonary hypertension and bronchoconstriction have multiple effects that overlap between factors
seen. The rationale for the administration of inhaled and are involved in the growth and differentiation of
NO in established ARDS is that it can cause local various cell types as well as the activation of cells
pulmonary vasodilation and bronchodilatation and to express specific protein synthesis. The important
thus improve oxygenation. Furthermore, any NO ab- factors in the development of ARDS and multiple
sorbed into the bloodstream will be immediately in- organ failure in vascular patients include tumor nec-
activated by haemoglobin and other proteins and rosis factor-a (TNF-a), interleukin- 1 (IL1), interleukin-
hence will not be able to exert its systemic effects.74–77 6 (IL-6) and interleukin-8 (IL-8).84–86
Endothelin is the most potent vasoconstrictor known. TNF-a is produced by many cells in the reticulo-
It is a family of peptides synthesised in response to endothelial system including monocytes, pulmonary
hypoxia, thrombin, noradrenaline and transforming macrophages and hepatic Kupffer cells in response to
growth factor beta. Endothelin causes vasoconstriction ischaemia reperfusion, shock, transient endotoxaemia
and encourages neutrophil–endothelial interactions. and sepsis.11,87 TNF-a acts by binding to specific re-
During physiological states the balance between the an- ceptors on a wide variety of cells. The actions of TNF-
tagonist effects of endothelin and nitric oxide regulate a include the release of neutrophils from the bone
vascular tone. This can be severely deranged, causing marrow, neutrophil activation and migration into the
vascular constriction and plugging of vessels during pulmonary endothelium by the upregulation of ad-
pathological states.78,79 hesion molecules and neutrophil free radical and pro-
tease production. TNF also stimulates the endotheliumPlatelet activating factor (PAF) is a phospholipid
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to synthesise PAF.88,,89 TNF-a promotes the dif- of total parenteral nutrition leads to villous atrophy,
billiary stasis and compromised gut immune function.ferentiation and activation of monocytes and macro-
phages, stimulates the formation of acute phase This in turn makes the host vulnerable to attack from
the potentially pathogenic gut flora.103proteins, activates the complement cascade and in-
duces the release of IL-1.90,91
Interleukin-1 is released in parallel or in response
to TNF. It stimulates the formation of granulocytes and
Blood transfusionmacrophages by inducing granulocyte/macrophage
colony stimulating factor. IL-1 also increases endo-
The complications of blood transfusion include fluidthelial–leucocyte interactions by up-regulating ad-
overload, transfusion related infection and ana-hesion molecules and potentiates leucocyte-mediated
phylactic reactions. Donor blood can activate hostdamage by stimulating free radical and lysozyme re-
defence mechanisms by the introduction of foreignlease.11,89 Interleukin-6 and IL-8 act synergistically with
antigens in donor leucocytes and platelets. The effectsTNF-a and IL-1 to modulate leucocyte-mediated lung
of a mild transfusion related reaction are often mani-injury.92 Interleukin-6 has been demonstrated to facili-
fested clinically as urticaria and pyrexia. Activation oftate endothelial–neutrophil adhesion.93 Interleukin-8 is
the host defence mechanism leads to upregulation ofproduced by endothelial cells and is a potent leucocyte
cytokines and neutrophil-induced acute lung injury.24chemoattractant.94
Transforming growth factor b is an angiogenic pep-
tide that inhibits neutrophil–endothelial adhesion, de-
activates macrophages and opposes the effects of TNF-
The systemic inflammatory response syndromea. Future work may find therapeutic use for this
factor.95
The systemic inflammatory response syndrome (SIRS)In addition to pro-inflammatory cytokines, cytokines
is defined by the presence of two or more of thewith predominantly anti-inflammatory actions have
following conditions: (a) temperature greater thanbeen identified. Interleukin-10 (IL-10) is one such cy-
38 °C or less than 36 °C; (b) heart rate greater than 90tokine that can inhibit TNF-a, IL-1 and IL-6. These
beats per minute; (c) respiratory rate greater than 20anti-inflammatory cytokines are involved in tightly
breaths per minute or an arterial partial pressure ofcontrolling the systemic inflammatory response.96
carbon dioxide lower than 4.3 kPa and (d) white blood
cell count greater than 12 000 or less than 4000 cells
per mm3 or with more than 10% immature forms.104
Non-cardiogenic pulmonary oedema is often an earlyEndotoxaemia and breakdown of the intestinal barrier
clinical manifestation of SIRS. Many of these patients
will go on to develop multiple organ failure.11Studies have demonstrated that elective and emer-
gency abdominal aortic aneurysm repair are associated The pathogenesis of SIRS has been described by
Bone to develop in three stages. The first stage is awith an increase in intestinal permeability.97 Colonic
ischaemia is an uncommon but lethal complication of normal response to an insult which may be any of
those seen in vascular surgical procedures includingabdominal aortic aneurysm repair.98 The splanchnic
vasculature is the last to recover following re- shock, haemorrhage, aortic cross-clamping, ischaemia
reperfusion injury, endotoxaemia, sepsis or bloodsuscitation from shock. All the above situations result
in a transient period of endotoxaemia.99,100 transfusion. The response to this insult is the pro-
duction of cytokines such that the host’s inflammatoryEndotoxin is a potent stimulus for the generation of
TNF-a and the proinflammatory interleukins. This in response is evoked to repair tissue damage by re-
cruitment of cells in the reticuloendothelial system.105turn leads to neutrophil mediated lung injury. It has
been argued by some that transient endotoxaemia is In the second stage of the development of the SIRS
small quantities of cytokines released into the cir-a powerful contributor to multiple organ failure after
major surgery, although others doubt its overall sig- culation recruit neutrophils and macrophages, and
initiate an acute-phase response. This response isnificance.101,102.
The intestinal barrier function depends on the nor- tightly controlled and is gradually downregulated (by
anti-inflammatory cytokines) while the initiating insultmal microbiological flora of the gut, enteric secretions,
peristalsis, the endothelium and gut-derived immune resolves.
If the initial insult persists, SIRS may develop andcells. These factors are markedly changed in critically
ill patients. Prolonged starvation or administration results in a large concentration of cytokines. The first
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clinical signs will be a temperature, tachycardia and propranolol, calcium antagonists and nafazatarom, but
none of these compounds have been found to be usefulnon-cardiogenic pulmonary oedema. The sustained
activation of the reticuloendothelial system results in in a clinical setting.111
Much of the research on the prophylactic preventionthe loss of microcirculatory integrity and eventual
multiple organ failure.105 of leucocyte–endothelial interaction has been directed
towards blocking adhesion molecules by antibodies
directed against them. Although these techniques are
Prevention of Acute Lung injury in Vascular effective in animal models, human studies have been
Surgery disappointing.
Systemic administration of heparin before the ap-
The key to preventing acute lung injury is to minimise plication of vascular clamps is common in clinical
factors that evoke a strong systemic inflammatory practice. Heparin inactivates proteins released from
response. In vascular surgical practice this would in- ischaemic tissues, prevents endothelial damage, neu-
clude the prevention of massive haemorrhage, shock tralises lysosomal cationic proteins released by leuco-
and the consequent need for large blood transfusions. cytes, limits the activation of complement and
Decreasing blood transfusion requirements may help promotes the formation of prostacyclin. Heparin also
limit the host’s response to foreign antigens. Pre- has antiplatelet and anti-inflammatory properties.
operative blood donation combined with haemo- These beneficial effects of heparin are due to its large
dilution and the salvage and retransfusion of size and negative charge, which prevents neutrophil–
autologous blood have been demonstrated as safe endothelial interactions.114–116
means of decreasing blood transfusion requirements Hetastarch, dextran and mannitol have also been
in aortic surgery.106,107 shown to protect against ischaemia-reperfusion in-
Aortic endovascular techniques avoid the need for duced lung injury in animal models by preventing
aortic cross-clamping and the consequent lower torso endothelial–leucocyte interactions.117–119
ischaemia-reperfusion injury. There is evidence to sug-
gest that endovascular aortic surgery evokes a smaller
systemic inflammatory response.108
A degree of transient endotoxaemia is associated
with aortic cross-clamping and haemorrhage but isch- Future Treatment Options Following the
Development of ARDSaemic colitis is an uncommon complication of ab-
dominal aortic reconstruction. The latter condition is
Current therapy for patients who develop post-often diagnosed late, and consequent endotoxaemia
usually leads to death from multiple organ failure.109 operative respiratory failure remains mainly sup-
portive. Supplementary oxygen and positive pressureA high index of suspicion seems to be the most useful
method of diagnosing and treating ischaemic colitis mechanical ventilation are critical to the maintenance
of adequate gas exchange. Prolonged oxygenation pro-early, the use of intrarectal pH monitoring being a
useful adjunct to early diagnosis.110 duces lung injury identical to that seen in other causes
of ARDS; furthermore, significant lung damage andThe prophylactic use of agents to minimise isch-
aemia reperfusion damage may be one method of barotrauma are complications of high transalveolar
pressures. Details of mechanical ventilation are outsidelimiting acute lung injury. Free radical scavengers
are agents that react with reactive oxygen species and the scope of this article, but some of the methods
used to provide adequate gas exchange while limitingneutralise them. Endogenous free radical scavengers
exist – namely superoxide dismutase. Many exo- inhaled oxygen consumption (FIo2) and ventilatory
pressures include providing a small tidal volume andgenous compounds including dimethylsulphoxide,
dimethylthiourea and histidine have been dem- optimal positive end–expiratory pressure.21,91,120–122
Other non-conventional methods of ventilatory sup-onstrated to inactivate free radicals in vitro or in
animal models;33,111 however, mannitol remains the port include high-frequency ventilation using breath-
ing frequencies up to 300 breaths per min,123 andmost reliable and proven exogenous free radical
scavenger in clinical practice.112 Allopurinol is an tracheal gas insufflation using a small continuous flow
of fresh gas from the distal endotracheal tube duringinhibitor of the enzyme xanthine oxidase, and there
are data to support its use at a low dose to prevent exhalation.124,125
Optimum fluid balance, inotropic support and thethe effects of ischaemia reperfusion injury.113
Antioxidants are compounds that stop lipid per- support of failing organ systems are specific to in-
dividual patients. Diagnosis of nosocomial pneumoniaoxidation and limit damage, e.g. vitamin E, captopril,
Eur J Vasc Endovasc Surg Vol 17, February 1999
Non-cardiogenic Pulmonary Oedema in Vascular Surgery 101
in these patients can be difficult and invasive tech- promoter of platelet aggregation) alone with keto-
konazole has been explored clinically with en-niques including bronchoscopy may be required to
couraging results.144 Prostaglandin E1 (PGE1) is aimprove diagnostic sensitivity.126
vasodilator that has been shown to improve gas ex-Selective decontamination of the digestive tract has
change and attenuate the release of free-radicals andbeen shown to reduce the rate of respiratory com-
cytotoxic enzymes from activated granulocytes.145 Re-plications in critically ill patients. The upper gastro-
cent pilot trials have demonstrated that inhaled PGE1intestinal tract is often colonised by endogenous
improved oxygenation and decreased venous ad-human gut flora in critically ill patients because of
mixture without affecting systemic haemodynamicduodenal reflux, bowel stasis and mucosal atrophy in
variables. The results were comparable to NO and thisthese patients. Aspiration of upper gastrointestinal
new form of treatment warrants a large multicentresecretions leads to respiratory complications and se-
randomised clinical trial.146,147lective gut decontamination may be protective.127 There
Surfactant depletion during acute lung injury isis debate about the value of early enteral feeding
responsible for alveolar collapse and decreased lungfollowing major surgery. Enteral feeding stimulates
compliance in progressive ARDS. Surfactant also hashepatic function and splanchnic blood flow, and may
important anti-inflammatory functions, including theprotect against acalculous cholecystitis and preserve
inhibition of TNF-a, IL-1 and IL-6 production by al-gut mucosal barrier and immunological function.128
veolar macrophages. The use of both natural andExogenous inhaled NO produces local vasodilation
artificial surfactant therapy is being studied, but, de-and reverses pulmonary vasoconstriction due to hy-
spite encouraging results in the use of this therapypoxaemia in ventilated parts of the lung. In patients
in neonatal acute lung injury, no benefit has beenwith ARDS, inhaling NO increases the arterial oxygen
demonstrated in adults.148,149tensions and decreases pulmonary hypertension,56,129
Other treatment strategies include the use of anti-and the benefits of this technique in infants and adults
oxidants to alleviate free-radical induced damage.with ARDS have been reported.130–133 Reported com-
Mannitol has been shown to reduce ischaemia-re-plications of inhaled NO include changes in platelet
perfusion induced end organ damage in humanfunction, worsening of left ventricular failure and
trials.112 Newer compounds being tested include N-rebound hypoxia on withdrawal. Levels of met-
acetylcysteine and an exogenous form of aerosolhaemoglobin, NO and NO2 have to be adequately superoxide-dismutase which may act locally in themonitored.134 Preliminary results of one large multi-
lung.91,150 A recent consensus committee documentcentred study has failed to demonstrate any improved
stated that steroids are not recommended in mostmortality.135 Inhaled NO as therapy for ARDS has to cases of ARDS.151
be used with caution till the full results of large clinical Ischaemic preconditioning is a physical method of
trials in Europe and the USA are published.136 limiting ischaemia-reperfusion damage. This phe-
Extracorporeal membrane oxygenation (ECMO) is nomenon is based on the observation that a series
a technique developed from cardiopulmonary bypass, of short ischaemic episodes followed by reperfusion
where an extracorporeal circuit provides oxygenation confers a degree of protection against further isch-
while the injured lungs are allowed to recover. How- aemia-reperfusion injury.152 The mechanism of isch-
ever, a multicentre trial in the 1970s failed to show aemic preconditioning is not fully understood, but the
any advantage of this technique over traditional vent- formation of adenosine during the ischaemic phase is
ilation.137 Despite improvements in the technology, a thought to be involved, and administration of exo-
recent trial has also failed to show any significant genase adenosine has some protective effects in ex-
benefits.138 perimental work. A further group of proteins called
Monoclonal antibodies directed against components heat-shock proteins have been implicated in ischaemic
of endotoxin have reduced mortality of patients with preconditioning, although the mechanism by which
Gram-negative sepsis139,140 but the results have not these stress proteins exert their protective effect has
been reproducible in a more recent study.141 Studies not been fully elucidated.153,154
attempting to antagonise the effect of IL-1 have failed
to demonstrate any clinical benefit.142 Prophylactic
haemofiltration has been performed as a method of
decreasing blood endotoxin and cytokine levels in Conclusions
patients at high risk of developing ARDS and multi-
organ failure.143 Aggressive preoperative control of cardiac function
together with better resuscitation and intensive-careAntagonism of thromboxane (a vasoconstrictor and
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